352 related articles for article (PubMed ID: 16941023)
1. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
2. Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.
Han SY; Hwang EA; Park SB; Kim HC; Kim HT
Transplant Proc; 2012 Apr; 44(3):657-60. PubMed ID: 22483462
[TBL] [Abstract][Full Text] [Related]
3. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.
Evenepoel P; Naesens M; Claes K; Kuypers D; Vanrenterghem Y
Am J Transplant; 2007 May; 7(5):1193-200. PubMed ID: 17359508
[TBL] [Abstract][Full Text] [Related]
4. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Barros X; Torregrosa JV; Martínez de Osaba MJ; Casals G; Paschoalin R; Durán CE; Campistol JM
Transplantation; 2012 Oct; 94(8):830-6. PubMed ID: 23018879
[TBL] [Abstract][Full Text] [Related]
5. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
[TBL] [Abstract][Full Text] [Related]
6. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
[TBL] [Abstract][Full Text] [Related]
7. Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients.
Prakobsuk S; Sirilak S; Vipattawat K; Taweesedt PT; Sumethkul V; Kantachuvesiri S; Disthabanchong S
Clin Exp Nephrol; 2017 Oct; 21(5):926-931. PubMed ID: 27981393
[TBL] [Abstract][Full Text] [Related]
8. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Serra AL; Wuhrmann C; Wüthrich RP
Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
[TBL] [Abstract][Full Text] [Related]
9. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.
Evenepoel P; Meijers BK; de Jonge H; Naesens M; Bammens B; Claes K; Kuypers D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1829-36. PubMed ID: 18922992
[TBL] [Abstract][Full Text] [Related]
10. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
[TBL] [Abstract][Full Text] [Related]
11. Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels.
Trombetti A; Richert L; Hadaya K; Graf JD; Herrmann FR; Ferrari SL; Martin PY; Rizzoli R
Eur J Endocrinol; 2011 May; 164(5):839-47. PubMed ID: 21335460
[TBL] [Abstract][Full Text] [Related]
12. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Ando K; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Ther Apher Dial; 2011 Oct; 15(5):481-7. PubMed ID: 21974702
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.
Wolf M; Weir MR; Kopyt N; Mannon RB; Von Visger J; Deng H; Yue S; Vincenti F
Transplantation; 2016 Jan; 100(1):184-93. PubMed ID: 26177089
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.
Kanaan N; Claes K; Devogelaer JP; Vanderschueren D; Depresseux G; Goffin E; Evenepoel P
Clin J Am Soc Nephrol; 2010 Oct; 5(10):1887-92. PubMed ID: 20634326
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients.
Caravaca F; Fernández MA; Ruiz-Calero R; Cubero J; Aparicio A; Jimenez F; García MC
Nephrol Dial Transplant; 1998 Oct; 13(10):2605-11. PubMed ID: 9794568
[TBL] [Abstract][Full Text] [Related]
18. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia.
Green J; Debby H; Lederer E; Levi M; Zajicek HK; Bick T
Kidney Int; 2001 Sep; 60(3):1182-96. PubMed ID: 11532115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
